Management of Tumor Lysis Syndrome in Patients With Multiple Myeloma During Bortezomib Treatment

Li Wang, BSN, Yuan Jian, BS, MMed, Guangzhong Yang, MD, Wen Gao, MS, MD, Yin Wu, BS, MS, and Lihong Zuo, BSN

Background: Tumor lysis syndrome (TLS) is a severe, life-threatening complication that typically occurs in highly proliferative malignancies. Although TLS is unusual in multiple myeloma (MM), it is still associated with significant morbidity. Bortezomib has been widely used for the treatment of MM with encouraging results, but TLS seems to occur more frequently in patients with MM receiving bortezomib than in patients receiving other conventional agents.

Objectives: The purpose of this article is to present and examine several significant risk factors for the development of TLS, based on the results of a study involving patients with MM who developed TLS during bortezomib treatment.

Methods: Patients with MM were treated with bortezomib-containing regimens.

Findings: The early identification and intervention of high-risk patients with MM is imperative. Timely and efficient management could decrease TLS incidence rates and improve the efficacy of treatment outcomes.

Caseto Report

From January to October 2013, 121 patients with MM were treated with bortezomib-containing regimens at Beijing Chao-Yang Hospital, which is affiliated with Capital Medical University in China. Of those patients, five developed TLS; three were women, and two were men. The median age of the five patients...